EN | UA
EN | UA

Help Support

Back

Seladelpar demonstrates its effectiveness in biliary cholangitis trial

Primary Biliary Cholangitis Primary Biliary Cholangitis
Primary Biliary Cholangitis Primary Biliary Cholangitis

What's new?

Seladelpar proved to be a promising therapy for patients with primary biliary cholangitis, previously known as primary biliary cirrhosis.

According to a novel clinical trial comprising of patients with primary biliary cholangitis, Seladelpar exhibited considerably superior biochemical response and alkaline phosphatase regularization as compared to the placebo. An improvement in moderate-to-severe itching (pruritus) was also observed with the use of this peroxisome proliferator-activated receptor delta agonist.

A total of 193 patients (with an inappropriate response to or with a history of undesirable side effects with Ursodiol) were randomized (2:1) to receive Seladelpar 10 mg orally every day or placebo.The main endpoint was achieving a biochemical response at one year, while secondary endpoints included normalizing alkaline phosphatase (ALP) levels at one year and evaluating differences in pruritus severity over six months for patients with moderate-to-severe itchiness at the beginning of the trial.

Of the total patients, 93.8% received Ursodiol as standard background therapy. Compared to the placebo group, more patients in the Seladelpar group encountered a biochemical response. Normalization of ALP levels was also more common in the Seladelpar group (P<0.001) as shown in Table 1:

Furthermore, Seladelpar resulted in a larger decrease in pruritus severity than placebo. The adverse events were described in 86.7% and 84.6% of patients in the Seladelpar and placebo groups, with severe events occurring in 7% and 6.2% correspondingly.

Source:

The New England Journal of Medicine

Article:

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Authors:

Gideon M Hirschfield et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: